Bifogade filer
Initiator Pharma attends BIO 2026 in San Diego
Prenumeration
Kalender
| Est. tid* | ||
| 2027-02-26 | 08:30 | Bokslutskommuniké 2026 |
| 2026-11-20 | 08:30 | Kvartalsrapport 2026-Q3 |
| 2026-08-21 | 08:30 | Kvartalsrapport 2026-Q2 |
| 2026-06-01 | - | X-dag ordinarie utdelning INIT 0.00 SEK |
| 2026-05-29 | - | Årsstämma |
| 2026-05-08 | - | Kvartalsrapport 2026-Q1 |
| 2026-02-20 | - | Bokslutskommuniké 2025 |
| 2025-11-21 | - | Kvartalsrapport 2025-Q3 |
| 2025-08-22 | - | Kvartalsrapport 2025-Q2 |
| 2025-05-26 | - | X-dag ordinarie utdelning INIT 0.00 SEK |
| 2025-05-23 | - | Årsstämma |
| 2025-05-09 | - | Kvartalsrapport 2025-Q1 |
| 2025-02-28 | - | Bokslutskommuniké 2024 |
| 2024-11-29 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-23 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-27 | - | X-dag ordinarie utdelning INIT 0.00 SEK |
| 2024-05-24 | - | Årsstämma |
| 2024-05-10 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-23 | - | Bokslutskommuniké 2023 |
| 2023-11-10 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-25 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-29 | - | X-dag ordinarie utdelning INIT 0.00 SEK |
| 2023-05-26 | - | Årsstämma |
| 2023-05-05 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-17 | - | Bokslutskommuniké 2022 |
| 2022-11-04 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-26 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-23 | - | X-dag ordinarie utdelning INIT 0.00 SEK |
| 2022-05-20 | - | Årsstämma |
| 2022-05-06 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-18 | - | Bokslutskommuniké 2021 |
| 2021-11-19 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-20 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-31 | - | X-dag ordinarie utdelning INIT 0.00 SEK |
| 2021-05-28 | - | Årsstämma |
| 2021-05-25 | - | Kvartalsrapport 2021-Q1 |
| 2021-05-11 | - | Extra Bolagsstämma 2021 |
| 2021-02-19 | - | Bokslutskommuniké 2020 |
| 2020-11-20 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-21 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-25 | - | X-dag ordinarie utdelning INIT 0.00 SEK |
| 2020-05-22 | - | Årsstämma |
| 2020-05-22 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-21 | - | Bokslutskommuniké 2019 |
| 2019-11-22 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-23 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-24 | - | X-dag ordinarie utdelning INIT 0.00 SEK |
| 2019-05-23 | - | Årsstämma |
| 2019-05-23 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-22 | - | Bokslutskommuniké 2018 |
| 2018-11-23 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-24 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-28 | - | X-dag ordinarie utdelning INIT 0.00 SEK |
| 2018-05-25 | - | Årsstämma |
| 2018-05-25 | - | Kvartalsrapport 2018-Q1 |
| 2018-03-01 | - | Extra Bolagsstämma 2017 |
| 2018-02-21 | - | Bokslutskommuniké 2017 |
| 2017-11-24 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-24 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-26 | - | Kvartalsrapport 2017-Q1 |
| 2017-05-17 | - | X-dag ordinarie utdelning INIT 0.00 SEK |
| 2017-05-16 | - | Årsstämma |
Beskrivning
| Land | Danmark |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Initiator Pharma A/S, a clinical-stage biotech company, today announced it will attend the BIO International Convention 2026, taking place on 22–25 June in San Diego, USA. Initiator Pharma’s CEO, Claus Olesen, will be available for meetings at the convention.
The BIO International Convention is the world’s largest partnering event for the global biotech industry, gathering more than 20,000 delegates annually from pharmaceutical companies, investors, and research organisations. The convention is a key meeting place for partnerships, licensing deals, and life sciences investments.
“BIO is a formidable arena for international business development in the biotech industry, and we enter this year’s convention in a stronger position within sexual health and neuropathic pain than ever before. The progress made in the vulvodynia study, the decision to fully commit to our lead asset pudafensine, and a strengthened IP position all contribute to a clearer and more compelling case,” says Claus Olesen, CEO of Initiator Pharma.
To book a meeting with Initiator Pharma during the convention, please contact ceo@initiatorpharma.com or use the BIO Partnering system.
For additional information about Initiator Pharma, please contact:
Claus Elsborg Olesen, CEO
Telephone: +45 6126 0035
E-mail: ceo@initiatorpharma.com
About Initiator Pharma
Initiator Pharma A/S is a Danish clinical stage emerging pharma company developing innovative drugs that target key unmet medical needs within the central and peripheral nervous system. Initiator Pharma’s pipeline consists of one clinical stage assets – pudafensine – and one preclinical asset. With pudafensine the company has reported positive, statistically significant and clinically relevant efficacy data in a Phase IIb clinical trial with patients suffering from ED.
Initiator Pharma is listed on Nasdaq First North Growth Market (ticker: INIT). Redeye Sweden AB is the company’s Certified Adviser. For more information, please visit www.initiatorpharma.com.